NC startup raises $17.5M as it explores alternative to the EpiPen


A Triangle pharmaceutical startup has raked in $17.5 million to fund commercialization of a nasal-spray that the company thinks could serve as an alternative to the EpiPen.

Previous Amazon acquires Health Navigator
Next With new degree, Suffolk Law looks to Boston’s booming biotech sector